TARS Stock Analysis: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$62.48
-2.70 (-4.14%)
▼
5d:
+2.07%
30d:
-7.74%
90d:
+2.8%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
TARS is down 8.0% this week, but smart money is accumulating calls. Top strike: $85 2026-07-17 with 336 OI. Call ratio: 100% View Scanner →
Strength: 9.0/10
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called TARS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TARS trading at deep discount. Market pricing in -17.3% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: TARS trading at deep discount. Market pricing in -17.3% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$95.85
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$59.52
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $62.48, which is considered slightly low relative to its 30-day fair value range of $60.92 to $69.22. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.8) compared to its historical average (40.3). Remarkably, the market is currently pricing in an annual earnings decline of 17.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TARS is in a strong downtrend. Immediate support is located at $57.81, while resistance sits at $66.79. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: TARS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $94.22 (+50.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TARS is in a strong downtrend. Immediate support is located at $57.81, while resistance sits at $66.79. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: TARS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $94.22 (+50.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$60.92 -
$69.22
Company Quality Score
59/100
(HOLD)
Options IV Signal
20th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
88.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 20th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 50.8% below Wall St target ($94.22)
Trading Range Analysis
30-Day Trading Range
$60.92 -
$69.22
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$4.49
(7.2%)
Support & Resistance Levels
Support Level
$57.81
Resistance Level
$66.79
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.83
Wall Street Target
$94.22
(+50.8%)
Revenue Growth (YoY)
106.9%
Profit Margin
-9.0%
Valuation Discount vs History
-17.3% cheaper
PE vs Historical
22.8 vs 40.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.3%
(market-implied from PE analysis)
1-Year Target
$56.23
(-10%)
2-Year Target
$50.61
(-19%)
3-Year Target
$45.55
(-27%)
3-Yr Target (if PE normalizes)
(PE: 23→40)
$80.39
(+29%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.8 to 40.3
Stabilization Target:
$110.27
(+76.5%)
PE Expansion Potential:
+76.5%
Share & Embed Analysis
Last updated: May 18, 2026 6:07 AM ET
Data refreshes hourly during market hours. Next update: 7:07 AM
Data refreshes hourly during market hours. Next update: 7:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Bryan Wahl
SELL
4231 shares
2026-03-19
Dianne C Whitfield
SELL
4174 shares
2026-03-19
Elizabeth Yeu Lin
SELL
390 shares
2026-03-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
